| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
A pharmacogenetic versus a clinical algorithm for warfarin dosing.
|
N Engl J Med
|
2013
|
7.09
|
|
2
|
CYP4F2 genetic variant alters required warfarin dose.
|
Blood
|
2008
|
4.23
|
|
3
|
A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose.
|
Blood
|
2008
|
4.02
|
|
4
|
Genetic variants associated with warfarin dose in African-American individuals: a genome-wide association study.
|
Lancet
|
2013
|
3.21
|
|
5
|
Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P450 2C9 gene polymorphisms on warfarin dose requirements.
|
Clin Pharmacol Ther
|
2006
|
3.06
|
|
6
|
Preserving the genetic integrity of human embryonic stem cells.
|
Nat Biotechnol
|
2005
|
3.03
|
|
7
|
Warfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3 racial groups.
|
Blood
|
2010
|
2.93
|
|
8
|
Large-scale gene-centric meta-analysis across 39 studies identifies type 2 diabetes loci.
|
Am J Hum Genet
|
2012
|
2.53
|
|
9
|
The Pharmacogenomics Research Network Translational Pharmacogenetics Program: overcoming challenges of real-world implementation.
|
Clin Pharmacol Ther
|
2013
|
2.39
|
|
10
|
beta-Adrenergic receptor polymorphisms and responses during titration of metoprolol controlled release/extended release in heart failure.
|
Clin Pharmacol Ther
|
2005
|
2.20
|
|
11
|
Regulatory polymorphism in vitamin K epoxide reductase complex subunit 1 (VKORC1) affects gene expression and warfarin dose requirement.
|
Blood
|
2008
|
2.18
|
|
12
|
Meta-analysis of Dense Genecentric Association Studies Reveals Common and Uncommon Variants Associated with Height.
|
Am J Hum Genet
|
2010
|
2.15
|
|
13
|
Large-scale gene-centric meta-analysis across 32 studies identifies multiple lipid loci.
|
Am J Hum Genet
|
2012
|
1.96
|
|
14
|
Pharmacogenomics: challenges and opportunities.
|
Ann Intern Med
|
2006
|
1.96
|
|
15
|
Plasma renin activity predicts blood pressure responses to beta-blocker and thiazide diuretic as monotherapy and add-on therapy for hypertension.
|
Am J Hypertens
|
2010
|
1.90
|
|
16
|
Stroke Genetics Network (SiGN) study: design and rationale for a genome-wide association study of ischemic stroke subtypes.
|
Stroke
|
2013
|
1.80
|
|
17
|
Statistical design of personalized medicine interventions: the Clarification of Optimal Anticoagulation through Genetics (COAG) trial.
|
Trials
|
2010
|
1.72
|
|
18
|
Chromosome 9p21 haplotypes and prognosis in white and black patients with coronary artery disease.
|
Circ Cardiovasc Genet
|
2011
|
1.69
|
|
19
|
G protein receptor kinase 4 polymorphisms: β-blocker pharmacogenetics and treatment-related outcomes in hypertension.
|
Hypertension
|
2012
|
1.59
|
|
20
|
Clinical pharmacogenetics implementation: approaches, successes, and challenges.
|
Am J Med Genet C Semin Med Genet
|
2014
|
1.57
|
|
21
|
Beta1-adrenergic receptor polymorphisms and left ventricular remodeling changes in response to beta-blocker therapy.
|
Pharmacogenet Genomics
|
2005
|
1.53
|
|
22
|
Hypertension susceptibility loci and blood pressure response to antihypertensives: results from the pharmacogenomic evaluation of antihypertensive responses study.
|
Circ Cardiovasc Genet
|
2012
|
1.52
|
|
23
|
Pharmacogenomic association of nonsynonymous SNPs in SIGLEC12, A1BG, and the selectin region and cardiovascular outcomes.
|
Hypertension
|
2013
|
1.52
|
|
24
|
Two CES1 gene mutations lead to dysfunctional carboxylesterase 1 activity in man: clinical significance and molecular basis.
|
Am J Hum Genet
|
2008
|
1.50
|
|
25
|
TET2 and CSMD1 genes affect SBP response to hydrochlorothiazide in never-treated essential hypertensives.
|
J Hypertens
|
2015
|
1.43
|
|
26
|
Genetic warfarin dosing: tables versus algorithms.
|
J Am Coll Cardiol
|
2011
|
1.43
|
|
27
|
Sustained restoration of autonomic balance with long- but not short-acting metoprolol in patients with heart failure.
|
J Card Fail
|
2006
|
1.41
|
|
28
|
KCNMB1 genotype influences response to verapamil SR and adverse outcomes in the INternational VErapamil SR/Trandolapril STudy (INVEST).
|
Pharmacogenet Genomics
|
2007
|
1.40
|
|
29
|
Genetic and pharmacogenetic associations between NOS3 polymorphisms, blood pressure, and cardiovascular events in hypertension.
|
Am J Hypertens
|
2009
|
1.40
|
|
30
|
A haplotype-based algorithm for multilocus linkage disequilibrium mapping of quantitative trait loci with epistasis.
|
Genetics
|
2003
|
1.31
|
|
31
|
Protocols for cytogenetic studies of human embryonic stem cells.
|
Methods
|
2008
|
1.30
|
|
32
|
Collection of genomic DNA by the noninvasive mouthwash method for use in pharmacogenetic studies.
|
Pharmacotherapy
|
2002
|
1.28
|
|
33
|
Loci influencing blood pressure identified using a cardiovascular gene-centric array.
|
Hum Mol Genet
|
2013
|
1.27
|
|
34
|
Highly variable mRNA expression and splicing of L-type voltage-dependent calcium channel alpha subunit 1C in human heart tissues.
|
Pharmacogenet Genomics
|
2006
|
1.27
|
|
35
|
Genetics and cardiovascular disease: a policy statement from the American Heart Association.
|
Circulation
|
2012
|
1.26
|
|
36
|
Creating and evaluating genetic tests predictive of drug response.
|
Nat Rev Drug Discov
|
2008
|
1.24
|
|
37
|
Sequencing complex diseases With HapMap.
|
Genetics
|
2004
|
1.22
|
|
38
|
Cholesteryl Ester Transfer Protein (CETP) polymorphisms affect mRNA splicing, HDL levels, and sex-dependent cardiovascular risk.
|
PLoS One
|
2012
|
1.21
|
|
39
|
Genetic and nongenetic factors associated with warfarin dose requirements in Egyptian patients.
|
Pharmacogenet Genomics
|
2011
|
1.20
|
|
40
|
Pharmacokinetics and CYP2D6 genotypes do not predict metoprolol adverse events or efficacy in hypertension.
|
Clin Pharmacol Ther
|
2004
|
1.20
|
|
41
|
Relation of beta(2)-adrenoceptor haplotype to risk of death and heart transplantation in patients with heart failure.
|
Am J Cardiol
|
2006
|
1.19
|
|
42
|
Effects of high-fructose corn syrup and sucrose on the pharmacokinetics of fructose and acute metabolic and hemodynamic responses in healthy subjects.
|
Metabolism
|
2011
|
1.15
|
|
43
|
Impact of abdominal obesity on incidence of adverse metabolic effects associated with antihypertensive medications.
|
Hypertension
|
2009
|
1.15
|
|
44
|
Synergistic polymorphisms of beta1 and alpha2C-adrenergic receptors and the influence on left ventricular ejection fraction response to beta-blocker therapy in heart failure.
|
Pharmacogenet Genomics
|
2007
|
1.15
|
|
45
|
Genomic association analysis of common variants influencing antihypertensive response to hydrochlorothiazide.
|
Hypertension
|
2013
|
1.14
|
|
46
|
Pharmacogenetics of beta-blockers.
|
Pharmacotherapy
|
2007
|
1.13
|
|
47
|
Chromosome 7 and 19 trisomy in cultured human neural progenitor cells.
|
PLoS One
|
2009
|
1.13
|
|
48
|
Rationale and design of the Clarification of Optimal Anticoagulation through Genetics trial.
|
Am Heart J
|
2013
|
1.12
|
|
49
|
Polymorphisms in genes coding for GRK2 and GRK5 and response differences in antihypertensive-treated patients.
|
Pharmacogenet Genomics
|
2011
|
1.12
|
|
50
|
Pharmacometabolomics reveals racial differences in response to atenolol treatment.
|
PLoS One
|
2013
|
1.10
|
|
51
|
Warfarin: an old drug but still interesting.
|
Pharmacotherapy
|
2008
|
1.08
|
|
52
|
Modeling sequence-sequence interactions for drug response.
|
Bioinformatics
|
2007
|
1.08
|
|
53
|
Role of carboxylesterase 1 and impact of natural genetic variants on the hydrolysis of trandolapril.
|
Biochem Pharmacol
|
2009
|
1.08
|
|
54
|
Differences in drug pharmacokinetics between East Asians and Caucasians and the role of genetic polymorphisms.
|
J Clin Pharmacol
|
2004
|
1.07
|
|
55
|
Alpha-adducin polymorphism associated with increased risk of adverse cardiovascular outcomes: results from GENEtic Substudy of the INternational VErapamil SR-trandolapril STudy (INVEST-GENES).
|
Am Heart J
|
2008
|
1.05
|
|
56
|
Comparison of cytochrome P450 2C9 genotyping methods and implications for the clinical laboratory.
|
Pharmacotherapy
|
2004
|
1.04
|
|
57
|
Human polymorphisms in the glutathione transferase zeta 1/maleylacetoacetate isomerase gene influence the toxicokinetics of dichloroacetate.
|
J Clin Pharmacol
|
2011
|
1.03
|
|
58
|
Cardiovascular pharmacogenomics.
|
Circ Res
|
2011
|
1.03
|
|
59
|
Association between the chromosome 9p21 locus and angiographic coronary artery disease burden: a collaborative meta-analysis.
|
J Am Coll Cardiol
|
2013
|
1.02
|
|
60
|
Genetics and genomics for the prevention and treatment of cardiovascular disease: update: a scientific statement from the American Heart Association.
|
Circulation
|
2013
|
1.01
|
|
61
|
Genetic variation in PEAR1 is associated with platelet aggregation and cardiovascular outcomes.
|
Circ Cardiovasc Genet
|
2013
|
0.99
|
|
62
|
Power to identify a genetic predictor of antihypertensive drug response using different methods to measure blood pressure response.
|
J Transl Med
|
2012
|
0.97
|
|
63
|
Warfarin pharmacogenetics: a rising tide for its clinical value.
|
Circulation
|
2012
|
0.97
|
|
64
|
Emerging roles for pharmacists in clinical implementation of pharmacogenomics.
|
Pharmacotherapy
|
2014
|
0.96
|
|
65
|
Genetic influence on exercise-induced changes in physical function among mobility-limited older adults.
|
Physiol Genomics
|
2014
|
0.95
|
|
66
|
Very important pharmacogene summary ADRB2.
|
Pharmacogenet Genomics
|
2010
|
0.94
|
|
67
|
Evaluating the genomic and sequence integrity of human ES cell lines; comparison to normal genomes.
|
Stem Cell Res
|
2011
|
0.94
|
|
68
|
CACNA1C gene polymorphisms, cardiovascular disease outcomes, and treatment response.
|
Circ Cardiovasc Genet
|
2009
|
0.94
|
|
69
|
Association of variants in NEDD4L with blood pressure response and adverse cardiovascular outcomes in hypertensive patients treated with thiazide diuretics.
|
J Hypertens
|
2013
|
0.91
|
|
70
|
Discordant beta-blocker effects on clinic, ambulatory, resting, and exercise hemodynamics in patients with hypertension.
|
Pharmacotherapy
|
2006
|
0.91
|
|
71
|
Lack of correlation between thiazide-induced hyperglycemia and hypokalemia: subgroup analysis of results from the pharmacogenomic evaluation of antihypertensive responses (PEAR) study.
|
Pharmacotherapy
|
2009
|
0.90
|
|
72
|
Simplified method for determination of clarithromycin in human plasma using protein precipitation in a 96-well format and liquid chromatography-tandem mass spectrometry.
|
J Chromatogr B Analyt Technol Biomed Life Sci
|
2008
|
0.90
|
|
73
|
Very important pharmacogene summary: thiopurine S-methyltransferase.
|
Pharmacogenet Genomics
|
2010
|
0.90
|
|
74
|
Very important pharmacogene summary: sulfotransferase 1A1.
|
Pharmacogenet Genomics
|
2009
|
0.89
|
|
75
|
Genetic nondiscrimination legislation: a critical prerequisite for pharmacogenomics data sharing.
|
Pharmacogenomics
|
2007
|
0.89
|
|
76
|
Factors influencing blood pressure response to trandolapril add-on therapy in patients taking verapamil SR (from the International Verapamil SR/Trandolapril [INVEST] Study).
|
Am J Cardiol
|
2007
|
0.89
|
|
77
|
Genetic variation in the beta2 subunit of the voltage-gated calcium channel and pharmacogenetic association with adverse cardiovascular outcomes in the INternational VErapamil SR-Trandolapril STudy GENEtic Substudy (INVEST-GENES).
|
Circ Cardiovasc Genet
|
2010
|
0.89
|
|
78
|
Aromatase gene polymorphisms are associated with survival among patients with cardiovascular disease in a sex-specific manner.
|
PLoS One
|
2010
|
0.89
|
|
79
|
CYP2C19 polymorphisms and therapeutic drug monitoring of voriconazole: are we ready for clinical implementation of pharmacogenomics?
|
Pharmacotherapy
|
2014
|
0.88
|
|
80
|
Is diabetes mellitus-linked amino acid signature associated with β-blocker-induced impaired fasting glucose?
|
Circ Cardiovasc Genet
|
2014
|
0.88
|
|
81
|
Urate transporter gene SLC22A12 polymorphisms associated with obesity and metabolic syndrome in Caucasians with hypertension.
|
Kidney Blood Press Res
|
2012
|
0.88
|
|
82
|
Effect of cytochrome P450 3A5 genotype on atorvastatin pharmacokinetics and its interaction with clarithromycin.
|
Pharmacotherapy
|
2011
|
0.88
|
|
83
|
Pharmacogenetics of chronic cardiovascular drugs: applications and implications.
|
Expert Opin Pharmacother
|
2006
|
0.88
|
|
84
|
Pathway analysis of genome-wide data improves warfarin dose prediction.
|
BMC Genomics
|
2013
|
0.87
|
|
85
|
Effects of genetic variation in H3K79 methylation regulatory genes on clinical blood pressure and blood pressure response to hydrochlorothiazide.
|
J Transl Med
|
2012
|
0.87
|
|
86
|
Blood pressure responses and metabolic effects of hydrochlorothiazide and atenolol.
|
Am J Hypertens
|
2011
|
0.86
|
|
87
|
Adrenergic gene polymorphisms and cardiovascular risk in the NHLBI-sponsored Women's Ischemia Syndrome Evaluation.
|
J Transl Med
|
2008
|
0.86
|
|
88
|
Carvedilol reduces aortic wave reflection and improves left ventricular/vascular coupling: a comparison with atenolol (CENTRAL Study).
|
J Clin Hypertens (Greenwich)
|
2011
|
0.86
|
|
89
|
Comparison of office, ambulatory, and home blood pressure antihypertensive response to atenolol and hydrochlorthiazide.
|
J Clin Hypertens (Greenwich)
|
2010
|
0.85
|
|
90
|
Single nucleotide polymorphism discovery and haplotype analysis of Ca2+-dependent K+ channel beta-1 subunit.
|
Pharmacogenet Genomics
|
2007
|
0.85
|
|
91
|
The evolving role of nesiritide in advanced or decompensated heart failure.
|
Pharmacotherapy
|
2003
|
0.85
|
|
92
|
Predictors for glucose change in hypertensive participants following short-term treatment with atenolol or hydrochlorothiazide.
|
Pharmacotherapy
|
2014
|
0.84
|
|
93
|
Gene-centric meta-analyses for central adiposity traits in up to 57 412 individuals of European descent confirm known loci and reveal several novel associations.
|
Hum Mol Genet
|
2013
|
0.84
|
|
94
|
Pharmacogenetics, pharmacogenomics, and cardiovascular therapeutics: the way forward.
|
Am J Cardiovasc Drugs
|
2002
|
0.84
|
|
95
|
Systolic blood pressure and subjective well-being in patients with coronary artery disease.
|
Clin Cardiol
|
2009
|
0.83
|
|
96
|
The influence of the CYP2C19*10 allele on clopidogrel activation and CYP2C19*2 genotyping.
|
Pharmacogenet Genomics
|
2014
|
0.83
|
|
97
|
Association of beta1-adrenergic receptor genetic polymorphism with mental stress-induced myocardial ischemia in patients with coronary artery disease.
|
Arch Intern Med
|
2008
|
0.83
|
|
98
|
A novel application of pattern recognition for accurate SNP and indel discovery from high-throughput data: targeted resequencing of the glucocorticoid receptor co-chaperone FKBP5 in a Caucasian population.
|
Mol Genet Metab
|
2011
|
0.83
|
|
99
|
Liver X receptor α gene polymorphisms and variable cardiovascular outcomes in patients treated with antihypertensive therapy: results from the INVEST-GENES study.
|
Pharmacogenet Genomics
|
2011
|
0.82
|
|
100
|
Genetic predictors of glucocorticoid-induced hypertension in children with acute lymphoblastic leukemia.
|
Pharmacogenet Genomics
|
2008
|
0.81
|
|
101
|
Lack of association between polymorphisms in STK39, a putative thiazide response gene, and blood pressure response to hydrochlorothiazide.
|
Pharmacogenet Genomics
|
2010
|
0.81
|
|
102
|
Future translational applications from the contemporary genomics era: a scientific statement from the American Heart Association.
|
Circulation
|
2015
|
0.81
|
|
103
|
Beta-blocker pharmacogenetics in heart failure.
|
Heart Fail Rev
|
2008
|
0.81
|
|
104
|
Assessment of human serotonin 1A receptor polymorphisms and SSRI responsiveness.
|
Mol Diagn Ther
|
2007
|
0.80
|
|
105
|
Influence of gender and race on hemodynamic response to dobutamine during dobutamine stress echocardiography.
|
Am J Cardiol
|
2004
|
0.80
|
|
106
|
Atenolol exposure and risk for development of adverse metabolic effects: a pilot study.
|
Pharmacotherapy
|
2010
|
0.80
|
|
107
|
PROX1 gene variant is associated with fasting glucose change after antihypertensive treatment.
|
Pharmacotherapy
|
2013
|
0.80
|
|
108
|
Pharmacogenomics of hypertension: a genome‐wide, placebo‐controlled cross‐over study, using four classes of antihypertensive drugs.
|
J Am Heart Assoc
|
2015
|
0.79
|
|
109
|
Impact of TCF7L2 single nucleotide polymorphisms on hydrochlorothiazide-induced diabetes.
|
Pharmacogenet Genomics
|
2013
|
0.79
|
|
110
|
Genotyping the GGGCGG tandem repeat promoter polymorphism in the 5-lipoxygenase enzyme gene (ALOX5) by pyrosequencing assay.
|
Genet Test Mol Biomarkers
|
2009
|
0.78
|
|
111
|
Association of diurnal blood pressure pattern with risk of hospitalization or death in men with heart failure.
|
J Card Fail
|
2007
|
0.78
|
|
112
|
Comparing marginal structural models to standard methods for estimating treatment effects of antihypertensive combination therapy.
|
BMC Med Res Methodol
|
2012
|
0.78
|
|
113
|
VKORC1 Asp36Tyr geographic distribution and its impact on warfarin dose requirements in Egyptians.
|
Thromb Haemost
|
2013
|
0.78
|
|
114
|
PharmGKB submission update: IX. ADRB1 gene summary.
|
Pharmacol Rev
|
2007
|
0.78
|
|
115
|
Altered beta-2 adrenergic receptor gene expression in human clinical hypertension.
|
Biol Res Nurs
|
2009
|
0.78
|
|
116
|
University of Florida Clinical and Translational Science Institute: transformation and translation in personalized medicine.
|
Clin Transl Sci
|
2011
|
0.78
|
|
117
|
Heart failure pharmacogenetics: past, present, and future.
|
Curr Cardiol Rep
|
2011
|
0.78
|
|
118
|
Atenolol induced HDL-C change in the pharmacogenomic evaluation of antihypertensive responses (PEAR) study.
|
PLoS One
|
2013
|
0.77
|
|
119
|
Association of branched and aromatic amino acids levels with metabolic syndrome and impaired fasting glucose in hypertensive patients.
|
Metab Syndr Relat Disord
|
2015
|
0.77
|
|
120
|
Night blood pressure responses to atenolol and hydrochlorothiazide in black and white patients with essential hypertension.
|
Am J Hypertens
|
2013
|
0.77
|
|
121
|
Impact of genetic polymorphisms of SLC2A2, SLC2A5, and KHK on metabolic phenotypes in hypertensive individuals.
|
PLoS One
|
2013
|
0.77
|
|
122
|
PTPRD gene associated with blood pressure response to atenolol and resistant hypertension.
|
J Hypertens
|
2015
|
0.76
|
|
123
|
Lack of association of the HMGA1 IVS5-13insC variant with type 2 diabetes in an ethnically diverse hypertensive case control cohort.
|
J Transl Med
|
2013
|
0.76
|
|
124
|
CYP2C9 promoter variable number tandem repeat polymorphism regulates mRNA expression in human livers.
|
Drug Metab Dispos
|
2012
|
0.76
|
|
125
|
Impact of the CYP2C19 genotype on voriconazole exposure in adults with invasive fungal infections.
|
Pharmacogenet Genomics
|
2017
|
0.75
|
|
126
|
Genome-Wide Prioritization and Transcriptomics Reveal Novel Signatures Associated With Thiazide Diuretics Blood Pressure Response.
|
Circ Cardiovasc Genet
|
2017
|
0.75
|
|
127
|
Re: Meckley LM, Veenstra DL. Screening for the alpha-adducin Gly460Trp variant in hypertensive patients: a cost-effectiveness analysis. Pharmacogenet Genom 2006; 16:139-147.
|
Pharmacogenet Genomics
|
2006
|
0.75
|
|
128
|
Clopidogrel and warfarin pharmacogenetic tests: what is the evidence for use in clinical practice?
|
Curr Opin Cardiol
|
2013
|
0.75
|
|
129
|
Combination antihypertensive treatment: is initiation order important?
|
J Clin Hypertens (Greenwich)
|
2010
|
0.75
|
|
130
|
Dobutamine pharmacodynamics during dobutamine stress echocardiography and the impact of beta-blocker withdrawal: a report from the Women's Ischemic Syndrome Evaluation Study.
|
Pharmacotherapy
|
2002
|
0.75
|